Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers

Documenti analoghi

• Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
  di: Irina Baltcheva, et al.
  Pubblicazione: (2026)
• Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies
  di: Alexandra A. J. Sillé, et al.
  Pubblicazione: (2026)
• Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience
  di: Juliette A. van den Noort, et al.
  Pubblicazione: (2025)
• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  di: Yuji Kumagai, et al.
  Pubblicazione: (2025)
• A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
  di: Yanina Hiriart, et al.
  Pubblicazione: (2024)